PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
33673653-0	2021	Investigation of the Impact of CYP3A5 Polymorphism on Drug-Drug Interaction between Tacrolimus and Schisantherin A/Schisandrin A Based on Physiologically-Based Pharmacokinetic Modeling.	Tacrolimus	84-94	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	31-37	
33673653-8	2021	An optimized physiologically-based pharmacokinetic (PBPK) model integrated with CYP3A5 polymorphism was successfully established, providing more insights regarding the long-term DDI between tacrolimus and Wuzhi capsules in patients with different CYP3A5 genotypes.	Tacrolimus	190-200	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	80-86	
33673653-8	2021	An optimized physiologically-based pharmacokinetic (PBPK) model integrated with CYP3A5 polymorphism was successfully established, providing more insights regarding the long-term DDI between tacrolimus and Wuzhi capsules in patients with different CYP3A5 genotypes.	Tacrolimus	190-200	cytochrome P450 family 3 subfamily A member 5	Homo sapiens	247-253